0001493152-26-012085
SEC filingMIRA Pharmaceuticals reported preclinical data showing Mira-55 produced no THC- or rimonabant-associated CNS side effects, including no psychogenic effects, sedation, catalepsy, motor impairment, or anxiogenic effects at oral doses of 10, 30, and 100 mg/kg. These results build on prior morphine-comparable pain relief in inflammatory pain models without opioid risks, supporting planned IND submission for inflammatory pain.